exactly - so the higher incidence of CDH17 over expression in GI cancers, the more patients that will be eligible for our CART treatment. This in turn means the addressable market out of the USD35 billion annual GI cancer market is higher. bingo!
I have seen some data on this elsewhere and the incidence quoted in the poster is somewhat higher than what I have seen elsewhere. Is it significant that CHM would commission its own study on this?
CHM Price at posting:
0.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)